Table 3.

Regression analysis* of change in mTSS from baseline at Month 12 by baseline risk factors.

Baseline Risk FactorLinear Regression of Change from BaselinepLogistic Regression of Proportion of Patients with > 0.5 Increase from Baselinep
Regression Coefficient (SE) [95% CI]Regression Coefficient (SE) [95% CI]OR (95% CI)#
CRP, mg/l0.0014 (0.002) [−0.002 to 0.005]0.4110.023 (0.01) [0.003–0.042]1.02 (1.00–1.04)0.023
DAPSA−0.0004 (0.003) [−0.006 to 0.005]0.8810.014 (0.023) [−0.031 to 0.059]1.01 (0.97–1.06)0.548
SJC0.0081 (0.007) [−0.005 to 0.021]0.2170.028 (0.054) [−0.078 to 0.135]1.03 (0.92–1.14)0.602
DSS−0.0090 (0.005) [−0.019 to 0.001]0.079−0.067 (0.049) [−0.163 to 0.028]0.93 (0.85–1.03)0.165
LEI0.0108 (0.020) [−0.029 to 0.051]0.596−0.089 (0.181) [−0.443 to 0.266]0.92 (0.64–1.30)0.624
mTSS−0.0003 (0.001) [−0.002 to 0.002]0.7670.005 (0.005) [−0.004 to 0.015]1.01 (1.00–1.02)0.274
PsA duration, yrs0.0054 (0.005) [−0.004 to 0.015]0.2740.019 (0.038) [−0.056 to 0.094]1.02 (0.95–1.10)0.617
  • * The linear or logistic regression analysis included fixed effects of baseline CRP, DAPSA, SJC, DSS, LEI, mTSS, PsA duration, and treatment sequences (tofacitinib 5 mg BID, tofacitinib 10 mg BID, placebo switched to tofacitinib 5 mg BID, placebo switched to tofacitinib 10 mg BID, and adalimumab) as covariates. A total of 380 patients were included in each analysis. Missing mTSS was imputed by linear extrapolation.

  • # The OR of progression is for 1 unit increase in the baseline risk factor. BID: twice daily; CRP: C-reactive protein; DAPSA: Disease Activity Index for Psoriatic Arthritis; DSS: dactylitis severity score; LEI: Leeds Enthesitis Index; mTSS: modified Total Sharp Score; PsA: psoriatic arthritis; SE: standard error; SJC: swollen joint count.